Advances in the Treatment and Clinical Management Strategies of Tuberculous Meningitis

被引:0
作者
Li, Rong [1 ,2 ]
Yin, Rong [2 ]
Li, Yuanming [2 ]
Wei, Yaxuan [2 ]
Zhao, Bin [2 ]
Ge, Chaoming [1 ]
机构
[1] Lanzhou Univ, Dept Neurol, Hosp 2, Lanzhou, Peoples R China
[2] Gansu Prov Cent Hosp, Dept Neurol, Lanzhou, Peoples R China
关键词
tuberculous meningitis; treatment strategies; drug selection; host-directed therapy; multidrug resistance; OUTCOMES; ASPIRIN;
D O I
10.2147/IJGM.S516998
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tuberculous meningitis (TBM), a central nervous system infection caused by Mycobacterium tuberculosis, is a rapidly progressing, insidious disease with an exceptionally high disability and mortality rate. Its significant global burden has become a critical focus in public health. The clinical diagnosis of TBM faces challenges due to the lack of specific symptoms and imaging characteristics, making early detection difficult. Combined with the shielding effect of the blood-brain barrier against anti-tuberculosis drugs and the issue of drug resistance, treatment outcomes are often suboptimal. Furthermore, current early sensitive diagnostic tools are inadequate, leading to delayed treatment for many patients and adversely affecting their prognosis. This paper reviews the pathophysiological mechanisms of TBM, the types and mechanisms of action of therapeutic drugs, and the common drug selection issues and safety challenges encountered in clinical practice. The aim is to provide comprehensive guidance and references for clinical diagnosis and treatment to improve the therapeutic outcomes and quality of life for TBM patients.
引用
收藏
页码:3267 / 3276
页数:10
相关论文
共 47 条
[1]  
Ai T, 2024, Zhonghua Er Ke Za Zhi, V62, P715, DOI 10.3760/cma.j.cn112140-20240524-00361
[2]  
[Anonymous], 2014, Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis
[3]  
Boyles Tom, 2019, Wellcome Open Res, V4, P19, DOI 10.12688/wellcomeopenres.15056.1
[4]  
Cresswell Fiona V, 2019, Wellcome Open Res, V4, P164, DOI 10.12688/wellcomeopenres.15506.1
[5]   Optimizing Pyrazinamide Use: A Low-Hanging Fruit in Improving Outcomes with Tuberculous Meningitis? Narrative Review [J].
Daniel, Bella Devaleenal ;
Inbaraj, Leeberk Raja ;
Kumaravadivelu, Shanmugapriya ;
Subramanian, Kathirvel ;
Ramraj, Balaji ;
Manesh, Abi .
INFECTIOUS DISEASES AND THERAPY, 2025, 14 (02) :317-325
[6]  
Davis Angharad G, 2021, Wellcome Open Res, V6, P136, DOI 10.12688/wellcomeopenres.16783.1
[7]  
Dian S, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/aac.01014-18, 10.1128/AAC.01014-18]
[8]   Cerebrospinal fluid concentrations of antituberculosis agents in adults and children [J].
Donald, P. R. .
TUBERCULOSIS, 2010, 90 (05) :279-292
[9]  
Donovan J, 2021, Wellcome Open Res, V6, P280, DOI [10.12688/wellcomeopenres.17154.1, DOI 10.12688/WELLCOMEOPENRES.17154.1]
[10]   Perplexing paradoxical reactions: navigating the complexity of protracted tuberculosis meningitis-a case report [J].
Gooding, Megan S. ;
Hammoud, Dima A. ;
Epling, Brian ;
Rocco, Joseph ;
Laidlaw, Elizabeth ;
Kuriakose, Safia ;
Chaturvedi, Mansi ;
Galindo, Frances ;
Ma, Stella V. ;
Mystakelis, Harry ;
Poole, April ;
Russo, Kelly ;
Shah, Maunank ;
Malone, Joseph L. ;
Rupert, Adam W. ;
Sereti, Irini ;
Manion, Maura .
FRONTIERS IN IMMUNOLOGY, 2024, 15